News und Analysen
![Cosmo presents strong H1 2023 operational and financial results](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Cosmo presents strong H1 2023 operational and financial results
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Methodist Jennie Edmundson Hospital Partners With Acadia Healthcare to Build New Behavioral Health Hospital in Council Bluffs: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGxvTXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9495f97191ece669fac2cb2dda5975e1824b4da8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ACHC.jpg?locale=de)
Methodist Jennie Edmundson Hospital Partners With Acadia Healthcare to Build New Behavioral Health Hospital in Council Bluffs
According to American Hospital Directory data, there is a shortfall of more than 300 inpatient behavioral health beds in Iowa and Nebraska.
To address this need, Methodist Jennie Edmundson
![Acadia Healthcare Forms Joint Venture Partnership With Nebraska Methodist Health System: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGxvTXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9495f97191ece669fac2cb2dda5975e1824b4da8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ACHC.jpg?locale=de)
Acadia Healthcare Forms Joint Venture Partnership With Nebraska Methodist Health System
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced today that it has formed a joint venture with Nebraska Methodist Health System to build a state-of-the-art, 96-bed behavioral health
![Convatec Group PLC: HOL-Holding(s) in Company](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Convatec Group PLC: HOL-Holding(s) in Company
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVZuV1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--08a59b30a4ec3d5c11e5a7197b8943d1e08dbea2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ALM_AW_LOGO_Tagline_MV_Positive_RGB_-281-29.jpg?locale=de)
Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.
Financial highlights (€ rounded million)
H1 2023
![Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzJBRWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5cbb888b15fc1babe89717dad3b9d241825019eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure_main-405x.jpg?locale=de)
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy of Tumor Treating Fields
![EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
![EQS-Adhoc: BB Biotech AG publishes its interim report](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
EQS-Adhoc: BB Biotech AG publishes its interim report
![Premier, Inc. to Report Fiscal 2023 Fourth-Quarter and Full-Year Results and Host Conference Call on August 22, 2023: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVVrRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c242cfb3032e071de8936910a6c2be2320576bb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/PR_LogoSpec_-282-29.jpg?locale=de)
Premier, Inc. to Report Fiscal 2023 Fourth-Quarter and Full-Year Results and Host Conference Call on August 22, 2023
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 fourth quarter and full year on Tuesday, August 22, 2023, at approximately 6:30 a.m. ET. The
![Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d12e73cbe17e88591f046adade2e976603e2e80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/charles_river_logo.jpg?locale=de)
Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2023 financial results on Wednesday, August 9th, before the market opens. A conference call has been scheduled
![Acadia Healthcare Opens the First of Two Hospitals Developed in Partnership With Geisinger: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGxvTXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9495f97191ece669fac2cb2dda5975e1824b4da8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ACHC.jpg?locale=de)
Acadia Healthcare Opens the First of Two Hospitals Developed in Partnership With Geisinger
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest operating joint venture hospital, Geisinger Behavioral Health Center Northeast, located in Moosic
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWRYRVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--91b049194ccf9261ff5ab4a8879b7c494da2dc48/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ICON_Positive_logo_PNG_-28nostrap-29.jpg?locale=de)
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has received positive recognition from leading business and industry organisations as a leading
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Chemed To Report Second-Quarter 2023 Earnings July 26, Related Conference Call To Be Held On July 27:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOW5FVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--74b99bf4056993cda09c937bd8d5cd0e22559956/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/branchen.png?locale=de)
Chemed To Report Second-Quarter 2023 Earnings July 26, Related Conference Call To Be Held On July 27
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2023, on Wednesday, July 26, 2023, following the close of trading on the
![Convatec Group PLC: Holding(s) in Company](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Convatec Group PLC: Holding(s) in Company
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVZuV1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--08a59b30a4ec3d5c11e5a7197b8943d1e08dbea2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ALM_AW_LOGO_Tagline_MV_Positive_RGB_-281-29.jpg?locale=de)
Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri® (tildrakizumab) significantly improved wellbeing in patients with
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Acadia Healthcare Announces Date for Second Quarter 2023 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGxvTXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9495f97191ece669fac2cb2dda5975e1824b4da8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ACHC.jpg?locale=de)
Acadia Healthcare Announces Date for Second Quarter 2023 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2023 results on Thursday, July 27, 2023, after the close of the market. Acadia will conduct a
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)